Diabetes News and Research

Latest Diabetes News and Research

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

Researchers from Mount Sinai School of Medicine are presenting more than 20 ground-breaking studies at the American College of Cardiology 59th annual scientific session (ACC.10) in Atlanta. Their research includes data showing that the World Trade Center collapse has caused potentially dangerous heart problems in responders on-site.

17 Mar 2010

Reversal of aging in normal human cells

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.”

17 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

Anti-obesity drugs fail to tackle wider issues of obesity

Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.

17 Mar 2010

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Generex Biotechnology Corporation (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).

17 Mar 2010

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Obesity has long been identified as a risk factor for cardiovascular disease and heart failure. But, a new study conducted by researchers at the University of Rochester Medical Center found that being skinny confers no advantage when it comes to the risk of dying suddenly from cardiac causes.

17 Mar 2010

Researchers evaluate novel organ sharing system that could help save more lives

Saint Louis University's Center for Outcome Research has received a $1 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to review regional kidney and liver distribution in the United States and equalize the access to transplantation among patients with similar stages of organ failure across the country.

17 Mar 2010

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

The Fonds de la recherche en santé du Québec in partnership with the Ministère de la Santé et des Services sociaux and Pfizer Canada, is announcing the creation of the Pfizer-FRSQ-MSSS Chronic Disease Fund. Established with an investment of $5 million from Pfizer Canada, this research grant program, coordinated by the FRSQ, is open to Quebec-based researchers who work in collaboration with health professionals.

17 Mar 2010

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.

16 Mar 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).

16 Mar 2010

Lexicon Pharmaceuticals announces pricing of public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the pricing of a public offering and concurrent private placement of its common stock in which the aggregate net proceeds to Lexicon will be approximately $165.0 million. The public offering consists of 87,717,391 shares of its common stock at a public offering price of $1.15 per share.

16 Mar 2010

Mortality in CAD patients: Key predictor identified

Coronary Artery Disease (CAD) hospitalizes more than 160,000 Canadians every year, and almost one quarter of those patients die from this common form of heart disease. But now a team of Vancouver-based researchers has identified a key predictor of mortality in CAD patients, which means that specialists can better determine how to treat and improve outcomes for patients with CAD.

16 Mar 2010

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta, Ga.

16 Mar 2010

Vitamin D supplements might do more harm than good for African-American patients

Vitamin D is quickly becoming the "go-to" remedy for treating a wide range of illnesses, from osteoporosis to atherosclerosis. However, new evidence from a Wake Forest University School of Medicine study suggests that supplementing vitamin D in those with low levels may have different effects based on patient race and, in black individuals, the supplement could actually do harm.

16 Mar 2010

Study suggests coffee can reduce chronic inflammation and raise ‘good' cholesterol

Multitudes of people worldwide begin each day with a cup of steaming hot coffee. Although it is sometimes referred to as "the devil's brew," coffee contains several nutrients (eg, calcium) as well as hundreds of potentially biologically active compounds (eg, polyphenols) that may promote health.

16 Mar 2010

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

16 Mar 2010

Arthritis drug could be useful for treating patients with type 2 diabetes

Clinical studies of a generic drug called salsalate, widely prescribed for arthritis, now provide early promising results that it may be useful for the treatment of patients with type 2 diabetes as well.

16 Mar 2010

NKF: Certain ethnic minorities are at higher risk for developing CKD

Certain ethnic minorities, including African Americans and Hispanics, are at a higher risk than the general population for developing potentially life-threatening chronic kidney disease (CKD), which has been linked to higher rates of diabetes and high blood pressure, according to the National Kidney Foundation.

16 Mar 2010

Unani.ca consumer-minded PEHR now available in Canadian marketplace

The McGill University Health Centre announced today that anyone with an Internet access and a desire to manage his or her health and well-being can now subscribe to Unani.ca. Co-developed with Quebec-owned Medical.MD, Unani.ca is the first consumer-minded personal electronic health record (PEHR) in the Canadian marketplace that combines the expertise of a world-class academic health centre with that of award-winning information-technology developers.

16 Mar 2010

Diabetes News and Research

Latest Diabetes News and Research

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

Reversal of aging in normal human cells

Pathway Genomics' personal Genetic Health Report now available

Anti-obesity drugs fail to tackle wider issues of obesity

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Researchers evaluate novel organ sharing system that could help save more lives

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Lexicon Pharmaceuticals announces pricing of public offering and concurrent private placement of common stock

Mortality in CAD patients: Key predictor identified

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Vitamin D supplements might do more harm than good for African-American patients

Study suggests coffee can reduce chronic inflammation and raise ‘good' cholesterol

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

Arthritis drug could be useful for treating patients with type 2 diabetes

NKF: Certain ethnic minorities are at higher risk for developing CKD

Unani.ca consumer-minded PEHR now available in Canadian marketplace

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in